Search research articles
Contact Us
Filters
Showing results (51-60 of 63) with videos related to
Page
of 7
Sort By:
Leukemia
|
December 26, 2023
Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification
Hélène Pasquer, Rafael Daltro de Oliveira, Loic Vasseur, et al.
British Journal of Haematology
|
October 10, 2022
Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study)
Lydia Roy, Jean-Claude Chomel, Joëlle Guilhot, et al.
The Lancet. Haematology
|
May 2, 2026
Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial
Franck E Nicolini, Gabriel Etienne, Françoise Huguet, et al.
Leukemia
|
June 18, 2025
A molecular signature predicts hematologic evolution in polycythemia vera patients
Olivier Mansier, Eric Lippert, Lina Benajiba, et al.
Hemasphere
|
September 8, 2025
Outcome of patients with accelerated and blast-phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination-A FIM study
Corentin Orvain, Suzanne Tavitian, Clémence Mediavilla, et al.
Leukemia
|
December 23, 2025
Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms
Alexandre Guy, Olivier Mansier, Matisse Decilap, et al.
The Lancet. Haematology
|
June 4, 2026
Prediction of bone marrow fibrosis from complete blood count in myeloproliferative neoplasms (FIBOM-AI): a multicentre machine learning model development and validation study
Marie Donzel, Syrine Khedimallah, Sabrina Barriere, et al.
Blood Advances
|
March 5, 2021
Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study
Damien Luque Paz, Jérémie Riou, Emmanuelle Verger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 17, 2012
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs
Robyn M Emanuel, Amylou C Dueck, Holly L Geyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 25, 2015
Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease
Holly Geyer, Robyn Scherber, Heidi Kosiorek, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 63) with videos related to
Sort By:
Page
of 7
Leukemia
|
December 26, 2023
Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification
Hélène Pasquer, Rafael Daltro de Oliveira, Loic Vasseur, et al.
British Journal of Haematology
|
October 10, 2022
Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study)
Lydia Roy, Jean-Claude Chomel, Joëlle Guilhot, et al.
The Lancet. Haematology
|
May 2, 2026
Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial
Franck E Nicolini, Gabriel Etienne, Françoise Huguet, et al.
Leukemia
|
June 18, 2025
A molecular signature predicts hematologic evolution in polycythemia vera patients
Olivier Mansier, Eric Lippert, Lina Benajiba, et al.
Hemasphere
|
September 8, 2025
Outcome of patients with accelerated and blast-phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination-A FIM study
Corentin Orvain, Suzanne Tavitian, Clémence Mediavilla, et al.
Leukemia
|
December 23, 2025
Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms
Alexandre Guy, Olivier Mansier, Matisse Decilap, et al.
The Lancet. Haematology
|
June 4, 2026
Prediction of bone marrow fibrosis from complete blood count in myeloproliferative neoplasms (FIBOM-AI): a multicentre machine learning model development and validation study
Marie Donzel, Syrine Khedimallah, Sabrina Barriere, et al.
Blood Advances
|
March 5, 2021
Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study
Damien Luque Paz, Jérémie Riou, Emmanuelle Verger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 17, 2012
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs
Robyn M Emanuel, Amylou C Dueck, Holly L Geyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 25, 2015
Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease
Holly Geyer, Robyn Scherber, Heidi Kosiorek, et al.
Page
of 7